Novo Nordisk cut its forecast for full-year 2016 profit growth and said it expected tough competition in the United States to pressure prices in 2017.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
A widely prescribed diabetes drug failed to reduce deaths or rehospitalizations in a study of patients with advanced heart failure.
U.S. pharmacy benefit manager CVS will drop Sanofi’s main insulin drug Lantus from the list of medicines it reimburses on behalf of health insurers.
Sanofi’s quarterly sales and profit fell despite double-digit growth at biotech arm Genzyme as the diabetes division came under sustained U.S. pricing pressure.
A study examining genes of more than 120,000 people from Europe, Asia, Africa and the Americas has offered the clearest picture yet of those that drive type 2 diabetes.
An FDA advisory panel will be asked to vote on whether a diabetes drug made by Eli Lilly and Boehringer Ingelheim cuts the risk of cardiovascular death, according to the agency’s website.
JERUSALEM, June 21, 2016 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced that Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT) is transferring a $6.5 million milestone payment from the previously-announced license and investment agreement between Oramed and HTIT. The payment follows Oramed’s positive top-line results […]
(Reuters Health) – A large weight loss, even if regained, may help overweight people with type 2 diabetes improve their blood sugar control and cholesterol and lower high blood pressure long-term, a new study suggests. Over four years, even those who regained all of a large weight loss had greater improvements in blood sugar than […]
Eli Lilly and Co’s Jardiance diabetes drug slashed the risk of progressive kidney disease in adults with type 2 diabetes in a large trial.
France’s Sanofi said two late-stage Phase III clinical trials of its LixiLan diabetes drug had met their targets, readying it for approval in the United States in August and Europe in early 2017.